HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes

Tasyurek, Hale M.; Eksi, Yunus Emre; Şanlioğlu, Ahter Dilşad; Altunbaş, Hasan; Balcı, Mustafa Kemal; Griffith, Thomas S.; Şanlıoğlu, Salih

doi:10.1038/s41434-018-0011-1

Cited by 12 publications

(11 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiapoptotic and insulinotropic functional properties of VIP have recently been demonstrated using a lentiviral vector (LentiVIP) in the animal model of T2DM. 38 To test these vectors in combination for STZ-induced diabetes, Len-tiINS and LentiVIP gene therapy vectors (LentiINSVIP) were delivered to diabetic Wistar rats to assess the efficacy of the combinatorial gene therapy approach in reducing blood glucose. Despite the significant reduction in non-fasting blood glucose of diabetic rats that received LentiVIP alone (compared to LentiLacZ-injected rats), concurrent administration of LentiINS and LentiVIP vectors were more effective than their individual injections (Figure 4A).…”

Section: Combinatorial Use Of Lentiins and Lentivip Vectors (Lentiinsvip) Was More Effective In Reducing Non-fasting Blood Glucose Than Tmentioning

confidence: 99%

“…[31][32][33][34] Currently, lentiviral vector-mediated therapeutic gene delivery is already underway for the treatments of both T1DM 35,36 and T2DM. 37,38 Recent studies concerning liver-directed gene therapy revealed that basal insulin requirements for T1DM could be met using lentivirus-mediated furin-cleavable insulin gene delivery to hepatocytes. 39,40 This approach was aimed at obviating the need for longacting insulin analogs in diabetic patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Combinatorial Use Of Lentiins and Lentivip Vectors (Lentiinsvip) Was More Effective In Reducing Non-fasting Blood Glucose Than Tmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…HIV-1 is the most extensively characterized human lentivirus used as the backbone for lentiviral-vectored gene therapies. 119,120 Compared to retroviral vectors, lentiviral vectors have superior properties, such as the ability to transduce diving and nondividing cells, high infection efficiency, and low probability of insertional mutagenesis. 121 Contrary to AAV (weakly immunogenic) and Ad-vectored (highly immunogenic) therapies, lentiviral vectors are fairly nonimmunogenic and provide long-term gene expression due to permanent integration into the host genome.…”

Section: Lentivirus Structure and Vector Designmentioning

confidence: 99%

Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

et al. 2021

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease (COVID-19) caused by the novel coronavirus SARS-coronavirus 2 (CoV-2). To combat the devastating spread of SARS-CoV-2, extraordinary efforts from numerous laboratories have focused on the development of effective and safe vaccines. Traditional live-attenuated or inactivated viral vaccines are not recommended for immunocompromised patients as the attenuated virus can still cause disease via phenotypic or genotypic reversion. Subunit vaccines require repeated dosing and adjuvant use to be effective, and DNA vaccines exhibit lower immune responses. mRNA vaccines can be highly unstable under physiological conditions. On the contrary, naturally antigenic viral vectors with well-characterized structure and safety profile serve as among the most effective gene carriers to provoke immune response via heterologous gene transfer. Viral vector-based vaccines induce both an effective cellular immune response and a humoral immune response owing to their natural adjuvant properties via transduction of immune cells. Consequently, viral vectored vaccines carrying the SARS-CoV-2 spike protein have recently been generated and successfully used to activate cytotoxic T cells and develop a neutralizing antibody response. Recent progress in SARS-CoV-2 vaccines, with an emphasis on gene therapy viral vector-based vaccine development, is discussed in this review.

show abstract

“…Expression of a mutant glucokinase (mGCK), which is an enzyme critical for glucose metabolism, by injection (SC) of adenovirus-based vector resulted in steady decrease in blood glucose over a long period (12-70 days) without inducing hypoglycaemia [66]. Expression of vasoactive intestinal peptide (VIP) by injection (IP) of HIV-based lentiviral vector encoding VIP improved insulin sensitivity, glucose tolerance, and reduced serum triglyceride/cholesterol levels [67]. ANGPTL8 gene delivery by ultrasound-targeted microbubble destruction promoted b-cells proliferation, expanded the b-cell mass, improved glucose tolerance, and increased the fasting blood insulin level in a diabetic rat model [68].…”

Section: Gene Therapy With Other Novel Targetsmentioning

confidence: 99%

Advances and potential of gene therapy for type 2 diabetes mellitus

Yue

Zhang

et al. 2019

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Gene therapy of type 2 diabetes mellitus (T2DM) and its complications has attracted intensive interest in recent years. In this paper, we critically review literature reports on gene therapy of T2DM published over the last five years. By reviewing these advances, three questions were addressed. First, which genes and how do they exert anti-diabetic effects? Target genes including that regulating glucose homeostasis, improving insulin secretion or sensitivity, and ameliorating diabetic induced complications are summarized. Second, how to deliver and which route is advantageous? All main methods that have been used for delivery of target genes into diabetic subjects are outlined and discussed regarding their pros and cons. Last, what are the future directions and how do these advances promote the study of T2DM gene therapy? Testing of novel targets in a parallel way and especially, using combinational approaches may be the main directions. In conclusion, there are a large number of genes playing important roles during the incidence and development of T2DM, and many of them hold great promise as potential targets for gene therapy. Oral delivery of target genes by probiotics may be a nice route with priority to develop, due to its high efficiency and safety for future gene therapy of T2DM. ARTICLE HISTORY

show abstract

HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes

Cited by 12 publications

References 55 publications

Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes

Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes

Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

Advances and potential of gene therapy for type 2 diabetes mellitus

Contact Info

Product

Resources

About